argenx Reports Phase 3 ALKIVIA Win in Myositis, Plans IMNM sBLA by Year-End
Efgartigimod met its primary endpoint in a combined myositis population, but statistical significance was seen in IMNM and not in dermatomyositis alone, shaping argenx's filing plans.
argenx has announced results from the Phase 3 ALKIVIA study of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in autoimmune myositis. The company released the topline data ahead of a late-breaking presentation at ACR Convergence 2026 on 11 November 2026.
The study met its primary endpoint in the combined population of immune-mediated necrotising myopathy (IMNM) and dermatomyositis (DM). At Week 52, patients on efgartigimod improved by 15.4 points more than those on placebo on the Total Improvement Score (TIS).
Looking at the subgroups, the result was statistically significant in IMNM but not in DM on its own. That split is likely to determine how the programme moves forward with regulators.
argenx plans to submit a supplemental Biologics License Application (sBLA) to the US FDA for IMNM by the end of 2026. The company says the filing will be supported by Breakthrough Therapy Designation, a status intended to speed development of products for serious conditions. It also reports a safety profile consistent with earlier efgartigimod studies.
Why it matters
- Regulatory teams should watch the sBLA, expected by end-2026, for how FDA handles a combined-population primary endpoint when only IMNM reached significance in the subgroup analysis.
- Market-access teams may need to plan for an IMNM-specific indication rather than a broad myositis label, based on the current data.
- Pharmacovigilance teams can note that the reported safety profile is consistent with prior studies, though full data are due at ACR Convergence 2026 on 11 November.
Company's press release (SEC filing): Argenx Se ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
IRulya Therapeutics reports $105.2M cash as LAM-001 Phase 2 readouts approach
Cerenome reports first CNSide revenue and completes enrolment in Phase 2 glioblastoma trial
BeyondSpring wins FDA Fast Track for plinabulin plus docetaxel in post-immunotherapy NSCLC
Valneva: 94% of adults still seroresponders five years after single IXCHIQ dose
GH Research posts $46.6M nine-month loss as GH001 depression programme nears pivotal stage
